Nevertheless, the pro-proliferative effect of MT4-MMP on breast cancer cells in vitro has been inhibited by erlotinib, and the presence of MT4-MMP in tumors was shown to be associated with more sensitivity to chemotherapy [59]. Here, MT4 is linked to breast cancer.